CA3129901C - Formulation d'anticorps therapeutique - Google Patents

Formulation d'anticorps therapeutique

Info

Publication number
CA3129901C
CA3129901C CA3129901A CA3129901A CA3129901C CA 3129901 C CA3129901 C CA 3129901C CA 3129901 A CA3129901 A CA 3129901A CA 3129901 A CA3129901 A CA 3129901A CA 3129901 C CA3129901 C CA 3129901C
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
formulation
patient
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3129901A
Other languages
English (en)
Other versions
CA3129901A1 (fr
Inventor
Vincent John Corvari
Karthik Pisupati
Galen Huaiqiu Shi
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority claimed from PCT/US2020/017594 external-priority patent/WO2020172002A1/fr
Publication of CA3129901A1 publication Critical patent/CA3129901A1/fr
Application granted granted Critical
Publication of CA3129901C publication Critical patent/CA3129901C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des formulations pharmaceutiques aqueuses stables pour des anticorps thérapeutiques et des procédés d'utilisation de telles formulations pharmaceutiques aqueuses stables.
CA3129901A 2019-02-18 2020-02-11 Formulation d'anticorps therapeutique Active CA3129901C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962807006P 2019-02-18 2019-02-18
US62/807,006 2019-02-18
US201962880846P 2019-07-31 2019-07-31
US62/880,846 2019-07-31
US201962947198P 2019-12-12 2019-12-12
US62/947,198 2019-12-12
PCT/US2020/017594 WO2020172002A1 (fr) 2019-02-18 2020-02-11 Formulation d'anticorps thérapeutique

Publications (2)

Publication Number Publication Date
CA3129901A1 CA3129901A1 (fr) 2020-08-27
CA3129901C true CA3129901C (fr) 2025-10-07

Family

ID=

Similar Documents

Publication Publication Date Title
US11634485B2 (en) Therapeutic antibody formulation
US11926670B2 (en) Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
US20240150479A1 (en) Liquid Pharmaceutical Composition Comprising an Anti-IL-6 Receptor Antibody
EP3506886B1 (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
KR20200037863A (ko) 고도로 농축된 저점도 masp-2 억제 항체 제제, 키트, 및 비정형 용혈성 증후군을 앓고 있는 대상체의 치료 방법
BR112021015034B1 (pt) Formulação de anticorpo terapêutico
EA045866B1 (ru) Состав терапевтического антитела
HK40039744A (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1258305A1 (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1258305B (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1188559A (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1188559B (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies